New Publication: Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group

/0 Comments/in , /by
We are happy to announce that CanREValue’s latest publication, Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group, has been accepted for publication in Current Oncology. Download a copy of this paper. Abstract The Canadian (more…)

New Publication: Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces

/0 Comments/in , /by
We are excited to share this three-province cost-effectiveness analysis of bevacizumab with first line combination chemotherapy in patients with metastatic colorectal cancer. View the full text at https://journals.sagepub.com/doi/full/10.1177/23814683211021060 Download a PDF copy by Clicking Here Authors: Reka E. Pataky , Jaclyn Beca , David Tran, Wei Fang Dai, Erind Dvorani, (more…)

Updated CanREValue Interim Methods Report + Response to Stakeholder Feedback now available!

/0 Comments/in , /by
As part of a broader engagement strategy, the CanREValue Collaboration has launched a stakeholder consultation process. In 2020, the CanREValue Collaboration undertook public stakeholder consultation regarding the Interim Methods Report developed by the CanREValue Methods Working Group. From this consultation, we received 13 constructive submissions from a diverse set of (more…)

Responses to Stakeholder Feedback re: CanREValue Interim Policy Report now available!

/0 Comments/in , /by
As part of a broader engagement strategy, the CanREValue Collaboration has launched a stakeholder consultation process. Earlier in 2020, the CanREValue Collaboration undertook public stakeholder consultation regarding the Interim Policy Report developed by the CanREValue Working Groups. From this consultation, we received 21 constructive submissions from a diverse set of (more…)

Updated CanREValue Interim Data Report now available!

/0 Comments/in , /by
As part of a broader engagement strategy, the CanREValue Collaboration has launched a stakeholder consultation process. In late 2019, the CanREValue Collaboration undertook public stakeholder consultation regarding the Interim Data Report developed by the CanREValue Data Working Group. From this consultation, we received 20 constructive submissions from a diverse set (more…)

New Publication: Real-world comparative effectiveness of 2nd line ipilimumab for metastatic melanoma…

/0 Comments/in , /by
ARCC and the CanREValue Collaboration are excited to share our recent study, using Ontario based real-world data to generate real-world evidence on the comparative effectiveness of 2nd line ipilimumab. Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada  Dai WF,  Beca JM, Croxford (more…)

CanREValue Interim Methods Report Open for Feedback

/0 Comments/in , , /by
The CanREValue Collaboration is pleased to open the feedback consultation period for our Methods Working Group report: CanREValue Collaboration Methods Working Group Progress Report on Real World Survival Data. View the Methods Working Group Report here Feedback Form Stakeholder input is essential to the development of a framework for the incorporation (more…)

New Publication: Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

/0 Comments/in /by
We are excited to report the publication of our manuscript Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration with BMJ Open. View the Article online with BMJ by clicking here Download a PDF copy directly by clicking (more…)

CanREValue Interim Policy Report Open for Feedback

/0 Comments/in , , /by
The CanREValue Collaboration is pleased to open the feedback consultation period for our Policy Working Groups: Developing a framework for incorporating real-world evidence into drug funding decisions: CanREValue Collaboration Policy Working Groups Interim Report 2019. View the Policy Working Groups Report here View the Report Appendix here Feedback Form Stakeholder input is (more…)

CanREValue Interim Data Report Open for Feedback

/0 Comments/in , , /by
The CanREValue Collaboration is pleased to open the feedback consultation period for our first Data Working Group Interim Report: Mapping Canadian Provincial Data Assets to Conduct Real-World Studies on Cancer Drugs. View the Interim Data Working Group Report here View the Report Appendix here Feedback Form We welcome any stakeholder (more…)